IP Library Granted Patent US 7,994,206
Granted Patent B2
US 7,994,206 · App. 12/168,331 · Granted Aug 9, 2011

Crystals and process of making 5-({[2-amino-3-(4-carbamoyl-2,6-dimethyl-phenyl)-propionyl]-[1-(4-phenyl-1H-imidazol-2-yl)-ethyl]-amino}-methyl)-2-methoxy-benzoic acid

Assignee: Janssen Pharmaceutica, N.V.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,994,206
App. No.
12/168,331
Granted
Aug 9, 2011
Kind
B2
Abstract

The present invention relates to a novel crystals of 5-({[2-amino-3-(4-carbamoyl-2,6-dimethyl-phenyl)-propionyl]-[1-(4-phenyl-1h-imidazol-2-yl)-ethyl]-amino}-methyl)-2-methoxy-benzoic acid and methods of making the zwitterion of 5-({[2-amino-3-(4-carbamoyl-2,6-dimethyl-phenyl)-propionyl]-[1-(4-phenyl-1h-imidazol-2-yl)-ethyl]-amino}-methyl)-2-methoxy-benzoic acid.

Claims (5)

1. A Form β crystal of 5({[2-amino-3-(4-carbamoyl-2,6-dimethyl-phenyl)-propionyl]-[1-(4-phenyl-1h-imidazol-2-yl)-ethyl]-amino}-methyl)-2-methoxy-benzoic acid, wherein said crystal is characterized by a powder X-ray diffraction patterns having powder X-ray diffraction peaks at about 11.0, 12.4, and 15.2 degrees 2-theta.

2. The β crystal of claim 1 , wherein said crystal is characterized by a powder X-ray diffraction pattern having powder X-ray diffraction peaks at about 11.0, 12.4, 14.9, 15.2, and 22.1 degrees 2-theta.

3. The β crystal of claim 1 , wherein said crystal is characterized by a powder X-ray diffraction pattern having powder X-ray diffraction peaks at about 11.0, 12.4, 14.9, 15.2, 22.1, 25.6, 27.4, and 30.4 degrees 2-theta.

4. A Form β crystal of 5-({[2-amino-3-(4-carbamoyl-2,6-dimethyl-phenyl)-propionyl]-[1-(4-phenyl-1h-imidazol-2-yl)-ethyl]amino}-methyl)-2-methoxy-benzoic acid wherein said crystal is characterized by a powder X-ray diffraction pattern having powder X-ray diffraction peaks substantially as shown in Table 2.

5. A Form β crystal of 5-({[2-amino-3-(4-carbamoyl-2,6-dimethyl-phenyl)-propionyl]-[1-(4-phenyl-1h-imidazol-2-yl)-ethyl]-amino}-methyl-2-methoxy-benzoic acid wherein said crystal is characterized by a powder X-ray diffraction pattern having powder X-ray diffraction peaks substantially similar to the powder X-ray diffraction peaks of FIG. 1 .

Assignments (6)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 8, 2016
From: FOREST TOSARA UNLIMITED COMPANY
To: ALLERGAN HOLDINGS UNLIMITED COMPANY
Reel/Frame 039370/0273 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 18, 2015
From: FURIEX PHARMACEUTICALS, LLC.
To: FURIEX HOLDINGS UNLIMITED COMPANY
Reel/Frame 036603/0168 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 18, 2015
From: FURIEX HOLDINGS UNLIMITED COMPANY
To: FOREST TOSARA LIMITED
Reel/Frame 036603/0236 →
CHANGE OF NAME Recorded Sep 18, 2015
From: FURIEX PHARMACEUTICALS, INC.
To: FURIEX PHARMACEUTICALS, LLC.
Reel/Frame 036640/0469 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 22, 2013
From: JANSSEN PHARMACEUTICA, N.V.
To: FURIEX PHARMACEUTICALS, INC.
Reel/Frame 030469/0881 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 9, 2009
From: ANZALONE, LUIGI; VILLANI, FRANK J.; TELEHA, CHRISTOPHER A.; FEIBUSH, PENINA; FEGELY, BARRY
To: JANSSEN PHARMACEUTICA, N.V.
Reel/Frame 022525/0367 →
Continuity (2)
Provisional Application 60948584 · Jul 9, 2007
Related Publication 20090018179A1 · Jan 15, 2009